Nikita Shah, MD
Surgical Oncology · Thousand Oaks, CANPI 1073889002
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,350 of the $1,897 with a category attached, or 71.2%. Eisai Inc. accounts for 73.6% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2020 at $1,350 and has fallen 92.9% since, to $95 in 2025. That places this record below the midpoint for surgical oncology clinicians in CA, where the typical reported total is $1,777.
Across 17 payments — averaging $111.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$1K
- Johnson & Johnson$164
- Myriad Genetic Laboratories, Inc.$117
- Merit Medical Systems Inc$95
- Myovant Sciences Inc.$63
- Tersera Therapeutics LLC$27
- plus $34 from 2 others
What the payments were for
- Consulting fees$1,35071%
- Food & beverage$54729%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 4 | $1,397 |
| Johnson & Johnson | 2 | $164 |
| Myriad Genetic Laboratories, Inc. | 4 | $117 |
| Merit Medical Systems Inc | 1 | $95 |
| Myovant Sciences Inc. | 3 | $63 |
| Tersera Therapeutics LLC | 1 | $27 |
| Cardinal Health 414 LLC | 1 | $18 |
| KCI USA, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,897 in reported general payments places this provider in the 50th percentile of 209 surgical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 30 | $90 |
Paid to pharmacies, not to this prescriber.
Other surgical oncology in Thousand Oaks
- David LitvakThousand Oaks$10K
- Afshin BahadorSan Diego$701K
- Amir FathiFresno$255K
- Alexander ChristSanta Monica$239K
- Yanghee WooDuarte$131K
- Michael BouvetSan Diego$118K
- Yuman FongDuarte$87K
- Ronald HurstLos Angeles$76K
- Jason Sicklickla Jolla$69K
- Mohammed Al-TemimiSan Jose$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.